Argenica Therapeutics Ltd

NEW
ASX:AGN (Australia)   Ordinary Shares
A$ 0.13 +0.0050 (+4.17%) Jul 10
At Loss
P/B:
4.64
Market Cap:
A$ 16.06M ($ 11.16M)
Enterprise V:
A$ 11.02M ($ 7.66M)
Volume:
402.82K
Avg Vol (2M):
373.83K
Trade In:
Volume:
402.82K
At Loss
Avg Vol (2M):
373.83K

Business Description

Argenica Therapeutics Ltd

ISIN : AU0000150328

Share Class Description:

ASX:AGN: Ordinary Shares
Description
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
Name Current Vs Industry Vs History
Cash-To-Debt
No Debt
Equity-to-Asset
0.66
Interest Coverage
No Debt
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate
-0.6
3-Year EPS without NRI Growth Rate
-0.6
3-Year Book Growth Rate
-16.4
Name Current Vs Industry Vs History
5-Day RSI
71.82
9-Day RSI
63.12
14-Day RSI
56.54
3-1 Month Momentum %
-29.03
6-1 Month Momentum %
-65.63
12-1 Month Momentum %
-83.82

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
2.96
Quick Ratio
2.96
Cash Ratio
2.87

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-13.9
Shareholder Yield %
-0.02
Name Current Vs Industry Vs History
ROE %
-123.15
ROA %
-92.9
ROIC %
-1724.3
3-Year ROIIC %
-1008.32
ROCE %
-123.15

Financials

ASX:AGN's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Argenica Therapeutics Ltd Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.077
Beta 2.0243
3-Year Sharpe Ratio -0.36
3-Year Sortino Ratio -0.48
Volatility % 81.36
14-Day RSI 56.54
14-Day ATR (A$) 0.009557
20-Day SMA (A$) 0.1074
12-1 Month Momentum % -83.82
52-Week Range (A$) 0.087 - 0.77
Shares Outstanding (Mil) 128.46

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Argenica Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Argenica Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Argenica Therapeutics Ltd Frequently Asked Questions

What is Argenica Therapeutics Ltd(ASX:AGN)'s stock price today?
The current price of ASX:AGN is A$0.13. The 52 week high of ASX:AGN is A$0.77 and 52 week low is A$0.09.
When is next earnings date of Argenica Therapeutics Ltd(ASX:AGN)?
The next earnings date of Argenica Therapeutics Ltd(ASX:AGN) is .
Does Argenica Therapeutics Ltd(ASX:AGN) pay dividends? If so, how much?
Argenica Therapeutics Ltd(ASX:AGN) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on Argenica Therapeutics Ltd

No articles.